Larimar Therapeutics
Biotechnology, Medical, Therapeutics
Founded in 1/1/05
Bala Cynwyd, Pennsylvania, United States
For Profit
About Larimar Therapeutics
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Company Metrics
- Employees: 11-50
- Monthly Visits: 295
- Tech Stack: 13 active products
Financial Information
- Estimated Revenue: $1M to $10M
- Total Funding: 320180000 USD
- Last Funding: 70000000 USD (Post-IPO Equity)
- Funding Status: IPO
Technology Stack
Larimar Therapeutics actively uses 13 products in their tech stack.
Market Presence
Industries: Biotechnology, Medical, Therapeutics
Headquarters: Bala Cynwyd, Pennsylvania, United States
Employees
- Gopi Shankar - Chief Development Officer (CDO) (LinkedIn)
- Mike Celano - Chief Financial Officer (LinkedIn)
- Nancy Ruiz - Chief Medical Officer & Head Non-clinical Toxicology (LinkedIn)